Gilead's EPS Guidance Plunges, Defying Wall Street

Forward-Looking Analysis

Gilead Sciences faces significant headwinds heading into its August 4, 2026, earnings report, primarily driven by a stark divergence between company guidance and Wall Street expectations. On May 7, 2026, Gilead updated its FY 2026 guidance, projecting an EPS range of -$1.05 to -$0.65. This forecast stands in sharp contrast to the consensus EPS estimate of $8.65, suggesting a potential miss or a substantial revision in analyst models is imminent. Revenue guidance is set between $30.0 billion and $30.4 billion, aligning closely with the consensus revenue estimate of $30.2 billion, indicating that while top-line performance may meet expectations, profitability is expected to contract significantly.

Analyst sentiment reflects this mixed outlook. While many firms maintain "Buy" ratings with price targets ranging from $152 to $180, notable downgrades and lower targets have emerged. Leerink Partners recently downgraded the stock to "Hold" with a $127 price target, implying a downside of -2.47% from recent levels. RBC Capital maintains a "Hold" rating with targets around $120-$122, signaling skepticism. Conversely, bullish analysts like Morgan Stanley and UBS maintain higher price targets of $165-$175, citing long-term value. The trailing P/E ratio of 17.74 suggests the stock is reasonably valued, but the EPS forecast for the next year is expected to jump from a loss of ($0.78) to $9.73, highlighting high volatility and uncertainty in the near term. Investors should focus on whether Q2 results bridge the gap between the negative guidance and current consensus estimates.

Historical Performance Review

In 2026Q1, Gilead Sciences demonstrated strong operational execution, reporting revenue of $6.96 billion, a 4.4% year-over-year increase that exceeded the $6.91 billion analyst consensus. Net income reached $2.02 billion, reflecting robust profitability despite a slight quarterly decrease. Earnings per share came in at $1.63 (noted as $2.03 in some reports, but $1.63 in financial stats), beating the $1.91 consensus by $0.12. Gross profit stood at $5.51 billion, underscoring the company's ability to maintain healthy margins while growing its top line, setting a high bar for the upcoming quarter.

Additional News

Gilead Sciences continues to position itself as a leader in treating life-threatening diseases, focusing on unmet medical needs in virology, oncology, and inflammation. The company’s portfolio includes key marketed products such as Biktarvy, Descovy, and Cayston, addressing HIV, viral hepatitis, and respiratory conditions. Recent corporate communications highlight a commitment to advancing medicines for conditions like cancer and COVID-19. The company maintains active investor relations, providing quarterly reports and SEC filings to keep stakeholders informed. While no specific new product launches or M&A activities were detailed in the immediate news cycle, the firm’s strategic focus remains on discovering and delivering innovative therapies. The company’s large market capitalization of $155.26 billion reflects its established position in the biopharmaceutical sector, with ongoing efforts to sustain its dominance in HIV treatments and expand into other therapeutic areas through its extensive R&D pipeline.

Summary & Outlook

Gilead Sciences exhibits a complex financial profile: strong Q1 revenue growth and gross margins contrast sharply with FY2026 EPS guidance indicating losses. The primary risk is the massive discrepancy between the -$1.05 to -$0.65 EPS guidance and the $8.65 consensus, suggesting potential structural changes or one-time charges. Growth catalysts include the stable revenue guidance and a diverse pipeline, but the negative earnings outlook introduces significant volatility. We maintain a neutral stance; while the company is fundamentally sound with a $155B market cap, the immediate earnings risk is high. Investors should await Q2 details to clarify if the negative guidance was an anomaly or a trend. The stock's valuation at a 17.74 P/E offers some cushion, but the earnings miss risk remains the dominant factor.